Drug intelligence / Profile preview

RK013

Development stage: Preclinical
Lead developer: RevolKa
Modality: Recombinant Proteins and Enzymes

Overview

RK013 is an investigational protein therapeutic being developed by RevolKa, a biotechnology company specializing in AI-driven protein engineering. The candidate is generated using RevolKa's proprietary 'evolvability' platform, which integrates directed evolution with machine learning to optimize protein functions and medicinal properties. As of early 2024, RK013 is in the research and development stage (categorized as 'Working' by the developer), though its specific molecular target and primary therapeutic indication have not been publicly disclosed.

Beyond the preview

Go deeper on RK013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RK013.

Explore the full profile